The ShiftShapers Podcast
Change either paralyzes or energizes - the choice is yours. Hear from businesses and entrepreneurs who have become energized and who have profited by shaping the shifts in their markets and practices. Become a SHIFTSHAPERS INSIDER and get our latest download, advance notice of all podcasts, podcast summaries, and special INSIDER-ONLY content. INSIDER SIGN UP
The ShiftShapers Podcast
Ep #119: Strategies and Tactics for Self-insured Plan Success - Part 2 - With Peter and Stacy Borans
Use Left/Right to seek, Home/End to jump to start or end. Hold shift to jump forward or backward.
It’s all about risk management! Learn how today’s successful plans incorporate clinical expertise, financial understanding, and cutting edge cost containment strategies to deliver outstanding year-over-year results.
Peter and Dr. Stacy Borans, provide the tools, techniques, strategies and tactics self-insured plans and their advisors need. The founders of Advanced Medical Strategies, they have over a decade of experience including independent medical reviews, claims cost containment, hospital negotiations, oncology services and claims repricing.
On this two-part series Peter and Stacy begin with a discussion of how the self-funded landscape has changed and what opportunities that provides for advisors – even those working in the smaller mid-market segment. We explore the high-level concepts and strategies that clients are finding successful and the concepts needed to have that initial and on-going self-insurance discussion with first-time self-insured groups.
Then we dig into a look at the biggest cost drivers: high-dollar claims, chronic disease and pharmacy spend. We also look to the future – a day when we will be doing more prospective than retrospective review, where predictive modeling will be far enough in front of potential claims so illness can be managed by looking out the windshield rather than viewed through the rear-view mirror. We also touch on the growing impact of reference-based pricing and the future of networks as we know them.
Join us on this second part of the conversation as we discuss how the fully insured vs. self-funded landscape is changing, as well as the essential concepts advisors need to understand in that arena. Don’t miss this opportunity to find out how you can deliver more value by bringing together clinical expertise, financial understanding, and cost containment.
What You’ll Learn From this Episode:
- Whether the fully insured vs. self-funded landscape is changing, and how.
- What concepts advisors need to understand.
- How a plan can handle high-dollar claims.
- The impact of chronic disease.
- How closely advisors should watch drug spend and what drives that component of claims costs.
- How we can start looking out the windshield rather than out the rear view mirror.
- How reference based pricing and narrow networks will impact claims.
How can you deliver more value by bringing together clinical expertise, financial understanding, and cost containment? We'll find out on this two-part episode of Shift Shapers.
SPEAKER_01Change either paralyzes or energizes. The choice is yours. You're listening to the Shift Shapers Podcast. You're about to learn firsthand from businesses and entrepreneurs who have successfully shaped the shifts in their industries. Get ready to become the change that you want to see. Here's your host and chief transformation strategist, David Saltzman.
DavidThis episode of Shift Shapers is brought to you by Benizon Healthcare Advocacy. Your clients and their employees expect more service, more responsiveness, and more help than ever before. You need to focus on building your book. How do you do both? Bennazon. To learn more, go to Benazon.com or click the Benizon logo at the top of the ShiftShapersOnline.com page. How can you be the first to know about each week's podcast and get on the list for special listener-only content? It's simple. Go to ShiftShapersonline.com and click the subscribe button. Even though millennials are kind of taking over the universe and now becoming a majority in the workforce, there are still economic conditions being such as they are. A significant cohort of baby boomers, older people who are managing chronic and oftentimes multiple chronic conditions. Is that something that advisors who get into this universe need to be aware of? How do they find those people and what kinds of things can they do when they do find them?
SPEAKER_00Well, that is a very interesting and complex question. So I'll sort of try to break that down. I would say you absolutely need to be aware of those particular people. You need to be aware of your folks who have chronic, ongoing, or expensive conditions. You need to be able to identify them. You need to be able to keep them well, first of all, and then you also need to be able to manage them when they start to have claims. And identifying them is actually fairly easy overall. You simply need to have either a case management company or a disease management company in place who can help you identify these folks. And you kind of look at every single chart in terms of top 10 most catastrophic conditions, and one, two, and three are cancer. And then it sort of falls off from there. Coronary artery disease as an example. And that kind of lags behind in number four. Premature babies are very expensive, but really impossible to predict. There's no way for you to know who's going to get pregnant in your group and whether or not they're going to be a high-risk pregnancy or somehow be at risk for preterm birth. But cancer, cancer, cancer is something that we can look at. And then all the things that sort of go along with some of the cardiac conditions and more chronic things like diabetes, et cetera. Diabetes in and of itself doesn't tend to be very expensive, but it's complications such as what we call end stage renal disease, where your kidneys stop working, that's inordinately expensive because dialysis is very expensive. You're actually better off from a financial perspective if that patient can get a kidney transplant versus being on dialysis for an entire year. It's actually less expensive to do that. But organs are tough to come by and dialysis is obviously readily available. So it is, I would say, most important to identify who is at a risk person for you. Put them in a program that allows them to be managed. Somebody is checking in with them, making sure that they're taking their medications. Compliance is the number one reason that patients tend to deteriorate. They're just not compliant. And why is that? Well, I will tell you, for a lot of people, it's cost. And not to digress too much, but kind of the big thing in our world in the past year has been the emergence of hepatitis C therapies. Hepatitis C has been around forever, truly forever. But it never was really a high dollar condition because most people, there weren't too many drugs available. There was basically two, which was interferon and ribivarin, and they're pretty pretty tough to take, particularly interferon. They have a lot of terrible side effects. They can cause what we call bone marrow suppression, where your red blood cells get decreased and your white blood cells decrease and your platelets decrease, and so people end up having to go off of them. And so a lot of times they couldn't complete the therapies. So you didn't really see too much in the way of costs. And then about three years ago, the market really broke wide open with the emergence of a lot of newer therapies, most of which are oral. And now we're at the point, and I won't go sort of through all the drugs otherwise, this would literally be a hepatitis C podcast. And I'm not sure your audience wants that. But if they do, we're happy to do it again just for you. I appreciate that. We do it a lot. It's a big, big topic. But there are about six or seven new drugs that have come out for hepatitis C, which have eliminated not only the interferon, but even now the ribivarin regimen. And they're all pills. And so you have all of these people who previously were either undiagnosed because they they weren't going to take the treatment anyway, because they, for whatever reason, they could they didn't want to do it or it wasn't going to work for them, or who just had failed therapy before. And there's an estimated somewhere in the neighborhood of 5 million people in our country who have hepatitis C. So you now have, I would say, probably more than half of those people who are now on these drugs. So hepatitis C has simply exploded, and the drugs are expensive. You take them for shorter periods of time, but they can cost anywhere from $90,000 to $100,000 for a 12-week course. Some of these people need to be on it for a lot longer, sometimes 24 weeks, or in patients who might need a liver transplant, you might see it for 48 weeks. So those dollars start to tick up to, you know, we're talking about that $367,000 claim for a patient who was in the hospital for seven days. Well, this is for somebody who's on hepatitis C therapy for a year while they're waiting a liver transplant. That's $700,000 to $800,000. And then you have to take into account the transplant. So it is important to identify who are those people who are going to be at risk for things that we may not have considered so risky before. And managing them is of paramount importance. When you can, not everybody can be can be managed, but when you can. And then if they end up in the hospital or needing some sort of treatment or have some sort of complication, truly aggressive intervention, proactive intervention is critical to making sure you got to be involved from day one at the hospital. You can't just try to figure it out once they get out of the hospital. Somebody should be on the phone with that facility saying, hey, this is our patient or our employee. They're in your hospital. Just want to let you know we're keeping an eye on the situation. There is really something about the specter of surveillance that uh keeps, you know, pretty much everybody, including hospitals, in some sort of check to a degree in which you can do that.
DavidWell, you talked about managing them. And at the risk of being naive here, let me ask a question. I think many practitioners who might not have had a lot of exposure in the tools that you can bring to bear in a self-insured universe. These are folks taking meds. How do you manage them? What do you do with those costs?
SPEAKER_00Well, there, you know, it's interesting because I think you sort of, in the way you asked the question, kind of illustrate the problem. A lot of people feel that there isn't a lot that you can do for when somebody is on a high-dollar medication. And I know we talked, you know, sort of about diabetics. There's a couple of fairly high dollar cholesterol medications that came out recently. And when you talk about folks who are hemophiliacs as an example, people who have factor eight deficiency where they have to get factor eight injections, those people are two and three million dollars a year. But there's a lot that you can do. There really is. And it's a mat, it's it's truly a matter of committing to do it. So some of the options that you have are when you know somebody's going to be on a high-dollar drug, look where you're getting it from. Try to source the drug from somewhere other than where you're paying in excess of 500, 600% above what you should be paying or 1,000% above what you're paying. There's a lot of specialty pharmacies out there that give you the ability to get drugs at a much cheaper price. So that's kind of the first thing that you can think of with drugs that are what we call specialty drugs. They're not your run-of-the-mill drugs. They're, they may be oral, but a lot of times they're they're intravenous, et cetera. But and there are ways to manage those types of drugs through specialty pharmacy. So that's option number one. If that's not an option for you, as an example, some physicians as well as some facilities won't let you bring drugs in from an outside vendor. You have to use their drugs. So well, now you're looking at reimbursing whatever their charges are. So you have to look for ways to contain those costs. So you can try to work directly with providers and negotiate with them up front if you know what the drug is and what the person's going to be on, or on the back end, kind of as as claims come in. So negotiation with a provider is an option. A lot of people like this as an option because it allows them to get sign off from a provider and you don't sort of have any issues with the patient being balance billed or kind of getting into a fight with the facility on the back end. But sometimes that's not going to give you the cost containment that you really need. So you can look at other things such as auditing these claims, where you can audit them to say reasonable charges. And I'm going to defer to Peter to talk about kind of how you figure out what a reasonable charge is.
DavidThat's a great question, Peter. How do you do that? I mean, it there's not a lot of information, despite all of our conversations around transparency and the need for that. Information still is really slow leaking out. So if you're a plan or if you're a claimant, how do you do that?
SPEAKER_02Yeah, that's really that's really one of the big, you know, we call it the black box, right? It's something goes in and that's it. It's still just a black hole. There are a number of different ways about it, and a big part of it is, you know, as you look towards self-funding, you have to be able to be partnering with the right constituents who are, you know, depth at doing these types of services. So you when you talk about monitoring and auditing and underwriting and all of these other things, a big piece of it comes down to as a patient and as an employer group, you have to be partnering with the right administrator who has the right folks who can start to give you these suites of services. So there's a number of ways that you're able to, you know, get something is into what's reasonable and customary. But it always comes down to the data sources. And there are a variety of different services, there are a variety of different sources that are out there that help you to be able to understand. The problem with them as they sit today, they're locked up tight and controlled by, you know, vendors. In some ways, they're also controlled by entities like the All Payers Claims Database. There's about 11 states that are now starting to collect all this data, and the average patient really can't get access to it. Just to get some kind of standard access can be upwards of $35,000. So right now it's all kind of locked up tight by the people who can afford to pay for it. But once you can get connected with the people who can afford to pay for it, then they're able to leverage those databases and the different sources that are out there to go around back to round back to the provider and say, look, if we're going to allow this to be paid, we need to be allowed it to be paid that's something considered reasonable and customary based on like providers in your geo zip code who provide the same level of service and care that you do. And when you start to look at those numbers, you can see a massive disparity between what is considered reasonable and customary. And you can pick a percentile if you, you know, if you want to be generous, you can say, well, we'll give you only 10% of the people who make more than you. You could say, hey, we want to kind of get you in the middle. Again, being self-insured allows you to do these things. So you also need to be able to have the plan documented and the benefit structure set up so that you can be afforded the opportunity to even leverage a reasonable and customary audit or a negotiation. What a lot of people don't understand and don't know the way things sit today is if you're in kind of that managed care world, you could be charged anything you want and you could even have access to the data. But the documents that underlie the benefit plan and how it gets administered and how the network contracts work would prohibit you from doing anything anyway. You could be charged, which we we've seen all the time. We've you could see something for $42 for one Advil, and the underlying documentation basically says, too bad, you have to reimburse us what you reimburse us. It doesn't matter that you can go buy three bottles of Advil totaling 1,500 pills for $42. Doesn't matter. So the data access, it's kind of locked up, it's expensive, but there are constituents within the payer chain, if you're partnered, that can actually help you leverage that. It exists, but it always becomes a fight because the provider doesn't really ever get held accountable for why they charge what they charge. They're allowed to arbitrarily charge whatever they want.
DavidAnd now, a word from our sponsor. Today, you're being pulled in multiple directions. Employers want you to deliver a higher level of service and employee satisfaction, and you want more time to grow your business. How do you do both? Venazon Healthcare Advocacy is the answer. Venizon helps plan members understand, utilize, and maximize their health plan, and answers their benefits questions while you improve productivity, increase client retention, and grow your book. The best part about partnering with Venazon is that your agency gets all the credit. Clients see your logo, while the Benizon team of subject matter experts work to ensure resolution to specific member information and service requests. Each agency gets a dedicated telephone number and year-round 24-7 customer support that answers the phone with your agency name. Turn your benefit on with Benazon. For more information, go to www.benizon.com or click their logo on the Shift Shapers website. Benazon. Healthcare as it should be. Now back to our interview. Do you see that changing anytime soon?
SPEAKER_02It's gonna have to change. They're scrambling in some ways now, right? The Affordable Care Act is supposed to, you know, kind of drive some of that change. But really what's happening is that because there's so much movement from that managed care world to self-funding, and when self-funding gets into that spot of being able to enact some kind of change, what you're seeing now is a whole sea change related to reference-based pricing. So they're being forced into it. So when you have groups and administrators and people getting together, putting them, you know, you hate to say it, but the proverbial skin in their game, throwing their hands up, posting a bill like this on a Reddit, and saying, you know, how do you even justify this? There's a groundswell now that says we're no longer going to take a top line percent off approach, which says, well, if we bill you $1,000 and you're in network and you get a 20% discount, you only have to pay us $800. What's happening now is that there's enough momentum and enough patients and enough administrators and enough people who have enough bodies to go to providers in their network in their area and say, we're no longer going to do that anymore. We're going to do what's called reference-based pricing, RBP, and we're going to take a benchmark that's out there and we're going to give you that number plus some amount. And what they're using right now is they're using Medicare. You know, CMS is a government entity that tracks all the different amounts that the government will pay to a provider for certain procedures and overall costs. So in the self-insurance world, they're saying, well, if the government's going to give you 50 cents for an Advil, we're going to give you 75 cents for an Advil. And when you have enough people saying, in order for you to get our business, then you have to accept this type of pricing. Those are one of the things that are out there right now where those types of changes are happening. You're also starting to see what's called very much narrow networks popping up. A lot of those narrow networks are solely focused on surgeries. Again, addressing the implant issue. You know, the the top three big areas of overinflation as it relates to costs are typically drugs, implants, and room charges can be, you know, can be a lot of it. And so, you know, the specialty drug issue is kind of, I don't want to say taken care of, but it's kind of being addressed by, as Dr. Warren said before, you know, uh pharmacy benefit management. Well, there's now this groundswell of narrow networks as it relates to surgeries, where they're going in and they're pre-negotiating all-encompassing surgery. You need a knee replacement. It is what it is. It's $15,000. It's already negotiated, it's one lump sum, where that knee surgery, under our typical scenario, would probably end up in a bill in excess of $75,000. So they're doing some of these things, but again, because they're in self-insured, they're able to kind of do some of those things. And I think Stacey2 can add a bit onto that as well.
SPEAKER_00Yeah, that'd be great. It's interesting because, as Peter mentioned, sort of moving towards these reference-based pricing, et cetera, doesn't really address the behavior, of course, of the providers, right? What are they going to do? Are they going to change how they're actually billing? Well, in reality, that's not what we're currently seeing in terms of what the providers are doing. So they they know that people are starting to limit their reimbursement to some sort of reference. And what they're doing is those the prices are still actually going up because obviously, if you're going to take some percentage of a reference, the higher your price is, the better off your percentage is. So the providers are certainly gaming the system. And you also have the additional problem of there's many things out there that don't have Medicare as a as a benchmark. And so people are sort of left floundering with, well, what am I going to do? And this is particularly of interest in the cancer world because the specialty drugs that come out for that, a lot of them, as I mentioned before, are oral pills. Medicare doesn't really have these sort of national coverage determinations for that. They really leave it to what they call their local contractors. And so you kind of have a lot of individual types of things going on, which leaves people scratching their head and saying, well, what am I going to do? What reference am I going to use if I can't use Medicare? And there are other things out there. We do a lot of audits that look at reasonable and customary and those types of things. And we use a lot of different national benchmarks that are out there that are really good and really defensible, which allow you, as you know, a client of ours or as a group or as an employer or as a TPA or whoever you are to go back to a provider and say, okay, this is kind of ridiculous. This is what we know a manufacturer is going to charge for this pill or what this pill is actually selling at, say, at a retail pharmacy. Your charges are really outrageous. And we're either going to, you know, dance together and come to some sort of compromise, or we're going to just unilaterally reimburse you what we think is fair and reasonable, and you can fight us out for it. Because they can try to go after the patient, and they certainly do threaten to go after the patient. But the reality is the patients aren't going to come up with any of the money. They're going to have to go after, you know, the deeper pockets, for lack of a better term. So we're seeing change more in provider behavior in terms of what they're willing to accept versus what they're really doing in terms of their charges. The shift is slow, definitely slow, but it's perceptible and things are moving. People are kind of fed up with, I'm just going to go through a network because they realize the networks aren't working on their behalf. The network is really trying to serve two masters. They contract both with a provider as well as with a payer. Well, you know, whose interests are you aligned with? Well, depending on how you're getting your money, if you're more aligned with the provider, where it makes more sense that higher dollars are going through your network because you're taking a percentage of that, you're not really incentivized to help the payer get those costs down because it's taking money out of your pocket. It's not as simplistic as, well, it's, you know, All the providers and and you know it's the it it's all one person. There are so many layers and it it becomes so complicated that trying to navigate through this, you really need some of this expert guidance to kind of get you through the fields.
DavidSo we've we've got about four or five minutes left. And one of the things that I think is a subtext in a lot of what we've been discussing today is starting to try to look forward rather than looking retrospectively. And with that, one of the things that gives us the most promise is this kind of up until recently murky field known as predictive modeling. Can we spend a couple of moments talking about predictive modeling as a strategy, what size cohorts you need for it to be viable, and what advisors ought to be looking for to try to get ahead of claims conditions?
SPEAKER_02Yeah, I mean, that is really as much as the data is uh we talk about it as it is a black box, but there is enough out there to be able to start to do some of these predictive analytics, which can hopefully drive some of the transparency. Because a lot of the problems we're talking about right now is transparency. Nobody knows, nobody understands, and you know, there's a universe of information out there. It's in completely disparate sources, and you can't really pull it all together. But there are options out there that are able to take all the clinical and all the financial and all the statistical data and put it together and create predictive modeling. And what brokers can be doing is getting in touch with those organizations who do predictive modeling, particularly as a plan moves from a fully insured managed care plan over to self-funding, because the key there is going to be identifying who are those people that will potentially capitulate the plan. And you can't do that unless you have predictive modeling. And where you want to focus those items on are the 200 or so diagnoses that are out there that can create that issue, which is create what we consider a catastrophic claim, or the 480 plus specialty pharmaceuticals, I think that's how many there are out there, that can run anywhere from $50,000 up to a million dollars a year. And there are options to be able to go out there and say, well, if I have this person who has this diagnosis or has been recently diagnosed with this, or is in the middle of the diagnosis and the pioneer happens to change, there are enough options out there to be able to take a look at it and say, within this diagnosis, within this person's state, within this person's network, and even specifically within their treatment, where they are in their treatment, you are able to see what's going to happen for the next 12 months. And one of the things that we talk about all the time is that knowledge becomes very, very powerful. Because if you know that going into it, imagine what you could do. You can pre-negotiate, you can move from one provider to another provider, you can plan reserves accordingly. The world opens up. And the way it kind of sits now is if you're in the broker field and you want to be in a very consultative fashion and you want to, you know, bring value to your groups and their pay and the patients that are part of those groups, being able to go to them and say, look, here are the people who are going to be a problem for your plan, and here's exactly why, you know, just drives so much value and squeezes excess dollars out of the whole payer chain that you desperately need. And quite frankly, they're wasted. And so by getting your hands on these types of analytical tools, the visibility that you have is it's tremendous. It's completely an eye-opening experience to be able to look at somebody and say, well, with this diagnosis of you know, be at breast cancer in Florida in this geographical zip code and you're down to radiation, don't worry about it. The most you're going to pay is $25,000 over the next 12 months is great. That knowledge becomes huge.
DavidWell, you know, there's no question that knowledge is power. I remember my one of my very first clients when I got into the insurance business back when dinosaurs roamed the earth, and we were still writing policies on cave walls, said to me once he was a physician, and he said, Patients will get off their knees when our doctors rather will get off their pedestals when patients get off their knees. That's right. That's right. You know, knowledge, knowledge is power. I I I cannot thank you guys enough for a very interesting discussion. We've been talking with Peter Borns and Dr. Stacy Borns from Advanced Medical Strategies. If you want to chat with them, we'll be featuring their logo as we always do in the right-hand column of the podcast website, Shift Shapers Online. Peter and Stacy, thank you so much for sharing your expertise with the Shift Shapers audience.
SPEAKER_00Thank you. We we enjoyed it. We love chatting about self-funding.
SPEAKER_02Thanks, David. Yeah, we have we have a lot of uh interesting topics that we covered today, and uh thanks for the opportunity.
DavidWell, and please come back. I'd like to continue the conversation.
SPEAKER_02We would too.
DavidThe Shift Shapers Podcast is a production of Strategic Vision Publishing and David Saltzman. This podcast may not be reproduced in any form, in whole or in part, without the express written permission of the producers. All rights reserved.